BE453374A - - Google Patents
Info
- Publication number
- BE453374A BE453374A BE453374DA BE453374A BE 453374 A BE453374 A BE 453374A BE 453374D A BE453374D A BE 453374DA BE 453374 A BE453374 A BE 453374A
- Authority
- BE
- Belgium
- Prior art keywords
- adrenochrome
- hemostatic
- stable
- derivatives
- aqueous
- Prior art date
Links
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical class O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 10
- 230000002439 hemostatic effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 claims description 4
- 229960002631 carbazochrome Drugs 0.000 claims description 4
- 229940030225 antihemorrhagics Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002874 hemostatic agent Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000000025 haemostatic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 125000004151 quinonyl group Chemical group 0.000 description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002478 diastatic effect Effects 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE453374A true BE453374A (enrdf_load_html_response) |
Family
ID=107750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE453374D BE453374A (enrdf_load_html_response) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE453374A (enrdf_load_html_response) |
-
0
- BE BE453374D patent/BE453374A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5059712A (en) | Isolating aminoarginine and use to block nitric oxide formation in body | |
| FR2484252A1 (fr) | Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau | |
| US5158883A (en) | Method of using aminoarginine to block nitric oxide formation in vitro | |
| BE897761A (fr) | Nouvelles compositions pharmaceutiques a base de cis-platine et procede pour les preparer | |
| FR2817750A1 (fr) | Composition pharmaceutique de dronedarone pour administration parenterale | |
| FR2511036A1 (fr) | Procede de preparation de derives d'insuline et produits obtenus | |
| BE453374A (enrdf_load_html_response) | ||
| JPS5835967B2 (ja) | 微細結晶ワルフアリンの製造方法 | |
| EP1037642B1 (en) | Modified polysaccharides exhibiting altered biological recognition | |
| CH666273A5 (de) | Verfahren zur herstellung einer neuen haemin-komplexverbindung und diese als wirksubstanz enthaltende pharmazeutische zubereitungen. | |
| RU2566065C2 (ru) | Комплекс гарцинола и циклодекстрина и способ его применения | |
| FR2458286A1 (fr) | Diluant pour le plasma, a base de pullulane | |
| JPH02223525A (ja) | 血管新生阻害剤 | |
| TW200908975A (en) | A medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol | |
| CH269341A (fr) | Procédé de préparation d'un dérivé hémostatique stable de l'adrénochrome. | |
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| EP4367124B1 (fr) | Procédé de préparation de diosmine et de fraction flavonoïque | |
| FR2638742A1 (fr) | Complexe forme a partir de sels de cations bivalents de l'acide acetylsalicylique et de l'uree - leur procede de fabrication, leurs applications therapeutiques basees sur les activites pharmacologiques | |
| BE817472Q (fr) | Procede pour la purification d'inhibiteurs de la kallikreine et de la trypsine | |
| FR2476488A2 (fr) | Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon | |
| LU83081A1 (fr) | Compositions antitumeurs | |
| FR2461498A1 (fr) | Procede de preparation de solutions concentrees d'amygdaline sous sa forme naturelle, et produits ainsi obtenus | |
| JPS59130866A (ja) | ピンドロ−ル製剤の製造法 | |
| BE510295A (enrdf_load_html_response) | ||
| BE536866A (enrdf_load_html_response) |